Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13,... The post Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update appeared first on Montreal Gazette .

Original source: Montreal Gazette